Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Company’s technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.